Valuation: BioNTech SE

Market Cap 19.2B 21.11B 17.76B 15.99B 30.19B 1,976B 31.34B 214B 84.45B 1,066B 79.23B 77.56B 3,367B P/E 2026 *
-12.2x
P/E 2027 * -15.2x
Enterprise Value 8.05B 8.85B 7.45B 6.7B 12.66B 828B 13.14B 89.56B 35.41B 447B 33.22B 32.52B 1,412B EV / Sales 2026 *
4.34x
EV / Sales 2027 * 5.02x
Free-Float
94.76%
Yield 2026 *
-
Yield 2027 * -
1 day-0.47%
1 week-3.03%
Current month-3.75%
1 month-3.25%
3 months-8.84%
6 months-5.24%
Current year-10.86%
1 week 84.23
Extreme 84.23
87.73
1 month 84.23
Extreme 84.23
92.73
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
374.58
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2017-12-31
Chief Executive Officer 61 2008-06-01
Director of Finance/CFO - 2025-06-30
Director TitleAgeSince
Chairman 56 2008-06-01
Director/Board Member 69 2008-06-01
Director/Board Member 65 2017-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/9/26 Sell

Chief Executive Officer

-36,209 0.0150%
10/7/26 Sell

Chief Executive Officer

-24,000 0.0099%
10/5/26 Sell

Chief Executive Officer

-72,000 0.0298%
Change 5-day change 1-year change 3-year change Capi.($)
-0.47%-3.03%-17.68%-14.88% 21.14B
+1.15%-2.81%+53.73%+71.00% 65.56B
-2.64%+0.07%+9.57%+89.87% 60.41B
-1.07%+0.55%+21.79%+87.66% 55.76B
+0.48%-0.98%+12.97%+118.46% 46.98B
-2.69%-7.62%+16.77%+25.79% 43.63B
-0.70%+1.43%+14.05%+45.20% 36.7B
-2.50%-18.72%+140.13%+665.60% 36.09B
-0.77%-4.34%+79.27%+59.47% 32.9B
-0.83%+4.96%-36.93%+398.61% 26.96B
Average -1.00%-1.79%+29.36%+154.68% 43B
Weighted average by Cap. -0.97%-1.54%+31.60%+140.17%

Financials

2026 *2027 *
Net sales 1.85B 2.04B 1.71B 1.54B 2.91B 191B 3.03B 20.62B 8.15B 103B 7.65B 7.49B 325B 1.86B 2.05B 1.72B 1.55B 2.92B 191B 3.04B 20.69B 8.18B 103B 7.67B 7.51B 326B
Net income -1.54B -1.69B -1.42B -1.28B -2.42B -158B -2.51B -17.1B -6.76B -85.32B -6.34B -6.21B -270B -1.23B -1.36B -1.14B -1.03B -1.94B -127B -2.01B -13.71B -5.42B -68.41B -5.08B -4.98B -216B
Net Debt -11.15B -12.26B -10.31B -9.29B -17.53B -1,147B -18.2B -124B -49.05B -619B -46.01B -45.04B -1,955B -9.87B -10.85B -9.12B -8.21B -15.51B -1,015B -16.1B -110B -43.38B -548B -40.7B -39.84B -1,730B
Projected Income Statement - Annual - BioNTech SE
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
26-11-17 $84.86 -0.47% 1,091,006
26-11-16 $85.26 -0.40% 1,036,185
26-11-13 $85.60 +0.66% 844,835
26-11-12 $85.04 -2.98% 979,096
26-11-11 $87.65 +0.50% 766,155
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - BioNTech SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
77.46EUR
Average target price
101.92EUR
Spread / Average Target
+31.59%
  1. Stock Market
  2. Stocks
  3. BNTX Stock